Journal
DRUG DISCOVERY TODAY
Volume 15, Issue 9-10, Pages 371-383Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2010.02.011
Keywords
-
Categories
Funding
- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [DK26741, DK070118]
- National Institute on Alcohol Abuse and Alcoholism [AA06420]
- Pearson Center for Alcoholism and Addiction Research
- Harold L. Dorris Neurological Research Institute
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070118, P01DK026741] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA006420, P60AA006420] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Corticotropin releasing factor (CRF) receptor antagonists have been sought since the stress-secreted peptide was isolated in 1981. Although evidence is mixed concerning the efficacy of CRF1 antagonists as antidepressants, CRF1 antagonists might be novel pharmacotherapies for anxiety and addiction. Progress in understanding the two-domain model of ligand-receptor interactions for CRF family receptors might yield chemically novel CRF1 receptor antagonists, including peptide CRF1 antagonists, antagonists with signal transduction selectivity and nonpeptide CRF1 antagonists that act via the extracellular (rather than transmembrane) domains. Novel ligands that conform to the prevalent pharmacophore and exhibit drug-like pharmacokinetic properties have been identified. The therapeutic utility of CRF1 antagonists should soon be clearer: several small molecules are currently in Phase II/III clinical trials for depression, anxiety and irritable bowel syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available